Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 169

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 169
---
 as well as patents covering sustained release drug delivery, nano-inclusion technology
and nanoparticle technology.

The term of individual patents depends upon the
legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is
20 years from the filing date of a non-provisional patent application. In the United States, a patent’s term may, in certain cases,
be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark
Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent.

The term of a United States
patent that covers a drug, biological product or medical device approved pursuant to a pre-market approval may also be eligible for patent
term extension when FDA approval is granted, provided that certain statutory and regulatory requirements are met. The length of the patent
term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Drug Price Competition
and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the expiration date set for the patent.
Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent
applicable to each regulatory review period may be granted an extension and only those claims reading on the approved drug may be extended.
Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved
drug, provided that statutory and regulatory requirements are met. Thus, in the future, if and when our product candidates receive approval
by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products,
depending upon the length of the clinical trials for each drug and other factors. The expiration dates of our patents and patent applications
referred to above are without regard to potential patent term extension or other market exclusivity that may be available to us.

In addition to patents, we
may rely, in some circumstances, on trade secrets to protect our technology and maintain our competitive position. However, trade secrets
can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with
our employees, corporate and scientific collaborators, consultants, scientific advisors, contractors and other third parties. We also
seek to preserve the integrity and confidentiality of our